Artal Group S.A. Arvinas, Inc. Transaction History
Artal Group S.A.
- $62.6 Million
- Q1 2025
Shares
1 transactions
Others Institutions Holding ARVN
# of Institutions
245Shares Held
62.5MCall Options Held
2.65MPut Options Held
1.1M-
Vanguard Group Inc Valley Forge, PA8.36MShares$61.5 Million0.0% of portfolio
-
Black Rock Inc. New York, NY6.26MShares$46.1 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il3.88MShares$28.5 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.83MShares$28.2 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY3.33MShares$24.5 Million0.38% of portfolio
About ARVINAS, INC.
- Ticker ARVN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,205,300
- Market Cap $392M
- Description
- Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...